|Bid||0.1750 x 0|
|Ask||0.1800 x 0|
|Day's Range||0.1750 - 0.1800|
|52 Week Range||0.1400 - 0.3800|
|Beta (5Y Monthly)||1.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 27, 2020 - Aug. 31, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.70|
TORONTO, ON / ACCESSWIRE / August 12, 2020 / Theralase® Technologies Inc.
Results of the First 12 patients enrolled in the Phase II NMIBC Clinical Study Demonstrate a 58.
TORONTO, ON / ACCESSWIRE / June 30, 2020 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers announces that after careful consideration the Company has decided to postpone its management information circular and the Annual General Meeting ("AGM"). In light of the COVID-19 pandemic and the restrictions on public gatherings enacted by both the Federal and Provincial governments in Canada to help protect the health and safety of its shareholders, employees and stakeholders, Theralase has elected to delay holding its 2020 AGM. The Company will be relying on the relief granted under Ontario Instrument 51-504 - Temporary Exemptions from Certain Requirements to File or Send Securityholder Materials, in connection with delaying the public filing of its executive compensation disclosure past the end of June 2020 filing deadline until the filing of its management information circular in connection with its next annual meeting of shareholders.